Publications
> >> Selected publications of David R. Hampson
>> Early Postnatal Expression Mitigates Immune Responses to Cas9 in the Murine Central Nervous System. Molecular Therapy, (2025) Robert Duba-Kiss and David R. Hampson (2025) Methods and Clinical Development, 33(3):10153 DOI: 10.1016/j.omtm.2025.1
>>> see journal Commentary on our article in this issue:
https://doi.org/10.1016/j.omtm.2025.101640
> Neonatal but not Juvenile Treatment with AAV Gene Therapy Reduces Seizures and Prolongs Lifespan in a Mouse Model of SCN1B-Dravet Syndrome. (2025) Chunling Chen, Yukun Yuan, Heather A. O'Malley, Robert Duba-Kiss, Yan Chen, Karl Habig, Yosuke Niibori, Samantha L. Hodges, David R. Hampson, and Lori L. Isom. Journal of Clinical Investigation, https://www.jci.org/articles/view/182584
>> CNS Dominant Human FMRP Isoform Rescues Seizures, Fear, and Sleep Abnormalities in Fmr1 KO Mice. (2023) Hayes Wong, Alexander W. M. Hooper, Hye Ri Kang, Shiron J. Lee, Jiayi Zhao, Chanchal Sadhu, Satinder Rawat, Steven J. Gray, and David R. Hampson. Journal of Clinical Investigation - Insight
https://insight.jci.org/articles/view/169650
> > In Silico Prediction and In Vivo Testing of Promoters Targeting GABAergic Inhibitory Neurons. (2023) Yosuke Niibori, Robert Duba-Kiss, Joseph T. Bruder, Jared B. Smith, and David R. Hampson. Molecular Therapy, Methods and Clinical Development, 28:330-343. https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(23)00009-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2329050123000098%3Fshowall%3Dtrue
> GABAergic Gene Regulatory Elements used in Adeno-associated Viral Vectors. (2021) Robert Duba-Kiss, Yosuke Niibori, and David R. Hampson
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.745159/full
> Gene therapy using an orthologue of human fragile X mental retardation protein partially rescues behavioural abnormalities and EEG activity. (2021) Alexander H. W. Hooper, Hayes Wong, Yosuke Niibori, Rozita Abdoli, Subha Karumuthil-Melethil, Chunping Qiao, Olivier Danos, Joseph Bruder, and David R. Hampson (2021) Molecular Therapy Methods and Clinical Development
https://www.cell.com/molecular-therapy-family/advances/fulltext/S2329-0501(21)00115-7
https://journal.frontiersin.org/article/10.3389/fnins.2015.00420
> Sexually Divergent Mortality and Partial Phenotypic Rescue after Gene Therapy in a Mouse Model of Dravet Syndrome. (2020) Yosuke Niibori, Shiron J. Lee, Berge A. Minassian, and David R. Hampson (2020). Human Gene Therapy, 31(5-6):339-351. doi: 10.1089/hum.2019.225
> The Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome. (2019) David R. Hampson, Alexander Hooper, and Yosuke Niibori (2019). Brain Science 2019, 9, 32; doi:10.3390/brainsci9020032
https://www.mdpi.com/2076-3425/9/2/32
> Interregulation between Fragile X Mental Retardation Protein and Methyl CpG Binding Protein 2 (2020) Jason Arsenault, Alexander W. M. Hooper, Shervin Gholizadeh, , Laura K Pacey, Enea Koxhioni, Yosuke Niibori, James H. Eubanks, Lu-Yang Wang, David R. Hampson (2020) . Human Molecular Genetics, 29(23): 3744-3756. doi: 10.1093/hmg/ddaa226.PMID: 33084871Jason Arsenault, Shervin Gholizadeh, Yosuke Niibori, Laura K. Pacey, Sebok K. Halder, Enea Koxhioni, Ayumu Konno, Hirokazu Hirai, and David R. Hampson. (2016) Human Gene Therapy 27(12), 982-996 (2016). DOI: 10.1089/hum.2016.090
Mammalian Susceptibility to a Neonicotinoid Insecticide after Fetal and Early Postnatal Exposure. Andrew P. Burke, Yosuke Niibori, Hayato Terayama, Masatoshi Ito, Charlotte Pidgeon, Jason Arsenault, Pablo R. Camarero, Carolyn L. Cummins, Rafael Mateo, Kou Sakabe, and David R. Hampson (2018) Scientific Reports (Nature Publishing Group), 8 (1),16639. https://www.nature.com/articles/s41598-018-35129-5